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Abstract
Background: Specific antibodies are likely to be present before S. pneumoniae infection. We explored cefditoren (CDN) total
and free values of serum concentrations exceeding the MIC (t.MIC) related to efficacy in a mice sepsis model, and the
effect of specific gammaglobulins on in-vitro phagocytosis and in-vivo efficacy.
Methodology/Principal Findings: We used three pneumococcal isolates (serotype, MIC of CDN): Strain 1 (6B, 1 mg/ml),
Strain 2 (19F, 2 mg/ml) and Strain 3 (23F, 4 mg/ml). Hyperimmune serum (HS) was obtained from mice immunized with heat-
inactivated strains. In-vitro, phagocytosis by HS diluted 1/10 in presence/absence of sub-inhibitory concentrations was
measured by flow cytometry including fluorescent bacteria and a neutrophil cell line. In-vivo dose-ranging experiments with
HS (dilutions 1/2–1/16) and CDN (6.25 mg/kg–100 mg/kg tid for 48 h) were performed to determine the minimal protective
dilution/dose (highest survival) and the non-protective highest dilution/dose (highest mortality: HS-np dilution and CDN-np
dose) over 7 days. Efficacy of CDN-np in animals pre-immunized with HS-np (combined strategy) was explored and blood
bacterial clearance determined. The CDN measured protein binding was 86.9%. In-vitro, CDN significantly increased
phagocytosis (vs. HS 1/10). In non pre-immunized animals, t.MIC values for CDN of <35% (total) and <19% (free) were
associated with 100% survival. Significant differences in survival were found between HS-np alone (#20%) or CDN-np alone
(#20%) vs. the combined strategy (90%, 60% and 60% for Stains 1, 2 and 3), with t.MIC (total/free) of 22.8%/14.3%, 26.8%/
16.0%, and 22.4%/12.7% for Strains 1, 2 and 3, respectively. Prior to the second dose (8 h), median bacterial counts were
significantly lower in animals surviving vs. dead at day 7.
Conclusions/Significance: In mice (CDN protein binding similar to humans) total t.MIC values of <35% (<19% free) were
efficacious, with a decrease in the required values in pre-immunized animals. This reinforces that immunoprotection to
overcome resistance may provide lifesaving strategies.
Citation: Cafini F, Yuste J, Gime ´nez M-J, Sevillano D, Aguilar L, et al. (2010) Enhanced In Vivo Activity of Cefditoren in Pre-Immunized Mice against Penicillin-
Resistant S. pneumoniae (Serotypes 6B, 19F and 23F) in a Sepsis Model. PLoS ONE 5(8): e12041. doi:10.1371/journal.pone.0012041
Editor: Michael Otto, National Institutes of Health, United States of America
Received April 26, 2010; Accepted July 9, 2010; Published August 10, 2010
Copyright:  2010 Cafini et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This study was supported by an unrestricted grant from Tedec-Meiji Farma S.A., Madrid, Spain. Tedec-Meiji Farma S.A. had a role in providing reagents,
materials and analysis tools.
Competing Interests: PC is an employee of Tedec-Meiji Farma S.A., Madrid (Spain). LA and MJG have received travel grants from Tedec-Meiji Farma S.A. (Madrid,
Spain) and LA and DS from Pfizer S.A. (Madrid, Spain) and Novartis Farmace ´utica S.A. (Barcelona, Spain) to attend different congresses for presentation of results
of different studies. LA has acted as a consultant for Tedec-Meiji Farma S.A. (Madrid, Spain). All authors confirm that these interests do not alter their adherence to
all the PLoS ONE policies on sharing data and materials.
* E-mail: laguilar@med.ucm.es
. These authors contributed equally to this work.
Introduction
Differences between in vitro activity and in vivo efficacy of
antimicrobials may result from the participation of the immune
system in bacterial eradication and/or the limitation of antibiotic
activity by the binding of antibiotics to serum proteins (protein
binding). Evidence shows that the successful outcome of infections
caused by Streptococcus pneumoniae in humans depends on the
humoral arm of the immune system (since opsonin/antibody-
dependent phagocytosis is the major defence mechanism against
S. pneumoniae) and on treatment with an adequate antibiotic.
Natural defences and antibiotics may act concomitantly when
using drugs as b-lactams acting on the cell wall that anchors the
capsule. Since colonisation is to some extend a B-cell immunising
event [1,2] and preventive measures as pneumococcal vaccina-
tion are increasingly being used, antibodies to capsular polysac-
charides (a surrogate marker of immunity) are likely to appear
before infection. In this situation, the appearance of pneumo-
coccal sepsis indicates defective protection against pneumococcal
invasion.
PLoS ONE | www.plosone.org 1 August 2010 | Volume 5 | Issue 8 | e12041All these facts were explored in previous mice sepsis models (using
a serotype 6B isolate non-susceptible to penicillin as infecting strain)
wherebacteremia with high colony counts was related with mortality,
and both (bacteremia and mortality) decreased in a dose-related trend
by administration of hyperimmune serum [3] or b-lactams
(amoxicillin or cefotaxime) [4]. When combined therapies (hyperim-
mune serum plus b-lactam) were explored, the strategy based on
passive immunisation (prior to infection) followed by b-lactam
administration post-infection was more effective than serotherapy
plus antibiotherapy post-infection [5]. Pharmacodynamically, passive
pre-immunisation of animals resulted in a significant reduction in the
value of the parameter predicting efficacy for b-lactams, i.e, the time
(% dosing interval) that serum concentrations exceed the MIC
(t.MIC) [6] when total drug was considered.
Despite pharmacokinetic differences between mice and humans,
animal models have been critical to our understanding of
pharmacokinetic/pharmacodynamic (PK/PD) relationships to esti-
mate which PK/PD parameter (t.MIC, AUC/MIC, Cmax/
MIC…) is the best predictor and the adequate magnitude of the
parameter. However, antibiotics with high protein binding require
special consideration since, classically, it is accepted that only the
unbound fraction of the compound is active in vitro and presumably
in vivo; the different proteinbindingrate inmiceandhumanslimiting
the extrapolation of results for high protein binding antibiotics.
Characterization of interactions between antibiotics and serum
proteins is essential in the assessment of pharmacodynamic
implications on antibacterial activity. The aims of this study,
using S. pneumoniae isolates from different serotypes (6B, 19F and
23F) with increasing MIC values, were to explore for cefditoren
(controlled with ceftriaxone for serotype 19F): a) Values of t.MIC
(total and free) related to efficacy in a mice sepsis model, taking
advantage of the similar high protein binding rate of cefditoren
(88%) in human and mice sera [7,8], b) The in vitro effect of sub-
inhibitory concentrations and specific antibodies on the interaction
of S. pneumoniae and phagocytes, and c) The in vivo effect of the
presence of specific antibodies to S. pneumoniae (passive immuni-
zation) on t.MIC values (total and free) related to therapeutic
efficacy in the mice sepsis model.
Results
Mice immunized with inactivated pneumococcal strains
produced antigen-specific serum antibodies
To evaluate the systemic humoral immune response to the
corresponding immunogenic suspension with the different strains
of the study, the levels of serum antigen-specific antibodies
generated by immunized mice, were compared to those of control
(non- immunized) mice. Antibody levels were very low in the
control group (59 mg/ml) whereas those obtained in the
immunized groups were serotype-specific with the immunogenic
suspension against the serotype 6B strain rendering the highest
levels of specific antibodies. Actually, overall IgG levels determined
in hyperimmune sera were 1056 mg/ml in animals immunized
against Strain 1 (serotype 6B), 371 mg/ml in those immunized
against Strain 2 (serotype 19F), and 251 mg/ml in those
immunized against Strain 3 (serotype 23F).
These results showed that immunized mice generated target-
specific antibodies in response to intraperitoneal immunization
with the different heat killed bacterial suspensions.
Cefditoren enhances opsonophagocytosis of
S. pneumoniae in the presence of specific antibodies
To explore whether subinhibitory concentrations of cefditoren
could increase the phagocytosis of S. pneumoniae by neutrophils in
the presence of specific antibodies, a flow cytometry assay was
performed. In phagocytosis assays measured by flow cytometry it is
important to analyse not only the percentage of positive cells but
also the amount of bacteria phagocytosed per neutrophil. To
address both parameters, results were expressed as a Fluorescence
Index (calculated as the geometric mean of the fluorescence
multiplied by the percentage of positive cells). The incubation of
pneumococcal strains with different subinhibitory concentrations
of cefditoren or ceftriaxone did not significantly (p.0.05) increase
phagocytosis compared to control samples that were incubated in
Hanks’ balanced salt solution (HBSS), which measure the level of
phagocytosis by the neutrophil itself in the absence of opsonins or
any other mediator (Fig. 1 and 2). The incubation of the different
Figure 1. In vitro opsonophagocytosis using HL-60 cell line. Flow cytometry histograms and the corresponding fluorescence indices showing
opsonophagocytosis for Strain 1 (A), Strain 3 (B), and Strain 2 with cefditoren (C) and ceftriaxone (D).
doi:10.1371/journal.pone.0012041.g001
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10) increased the uptake of S. pneumoniae in experiments using HL-
60 cells with all strains (Fig. 1) and in those using mice neutrophils
with Strains 1 and 3 (Fig. 2). In addition, the incubation of S.
pneumoniae with subinhibitory concentrations of cefditoren in the
presence of specific antibodies significantly increased the phago-
cytosis against the three strains compared to the phagocytosis
mediated by the 1/10 dilution of hyperimmune serum or the
subinhibitory antibiotic concentrations independently, both using
HL-60 (p,0.03) (Fig. 1A–C) and mice neutrophils (p#0.001)
(Fig. 2A–C). This was not the case of ceftriaxone and Strain 2
where the phagocytosis mediated by HL-60 cells was not
statistically different (p=0.2) from the one mediated by the 1/10
dilution of hyperimmune serum itself (Fig. 1D), although in
experiments with mice neutrophils the phagocytosis with 0.256
MIC was significant (p=0.012) but not with 0.56MIC (p=0.1)
(Fig. 2D). Overall, these results suggest that in the presence of
specific antibodies to S. pneumoniae, the addition of subinhibitory
concentrations of cefditoren increased the efficiency of phagocy-
tosis mediated by professional phagocytes.
Efficacy obtained with antibiotic treatment is improved
in the presence of specific antibodies
Survival experiments were performed using a mice sepsis model
of infection. Minimal lethal doses, producing 100% mortality rates
over a 7-day follow-up period, were 3.5610
7 cfu/ml for Strain 1,
1.6610
7 cfu/ml for Strain 2 and 4.7610
6 cfu/ml for Strain 3.
To explore the protective capacity of the hyperimmune sera,
groups of animals were immunized with different dilutions of the
sera 1 h before challenge with a lethal dose of the corresponding
bacteria and survival was followed for 1 week. In passively
immunized animals (with the 1/8 or 1/4 dilutions) that did not
receive antibiotic treatment, the survival rate was 0% in animals
infected with Strains 1 and 3 and 20% in those inoculated with
Strain 2. With the 1/2 dilution, percentages of survival were 40%
for Strains 1 and 2, and 20% for Strain 3. Therefore, the first
dilution showing 100% (or the highest) mortality, that was
considered the non-protecting dilution of hyperimmune serum
(HS-np), was 1/4 for Strains 1 and 2 and 1/2 for Strain 3 (Tables 1
and 2).
The protection conferred by the antibiotics of the study was
investigated in the sepsis model. Groups of mice were challenged
with a lethal dose of the corresponding strain and 1 h later
antibiotic treatment was initiated, with administration at 8 h
intervals for a total of 6 doses. Treatment with 50 mg/kg of
cefditoren in animals infected with Strain 1 or 100 mg/kg in
animals infected with Strain 2 produced 100% survival rates, while
in those infected with Strain 3, the 100 mg/kg regimen only
produced 60% survival (Tables 1 and 2). The highest cefditoren
doses that produced the lowest survival rate (i.e, antibiotic non-
protective doses - A-np) were 12.5 mg/kg for Strain 1 (0%
survival) and 50 mg/kg for Strain 2 (0% survival) and 3 (20%
survival). In the case of ceftriaxone and Strain 2 (MIC=4 mg/ml),
100% survival was obtained with 25 mg/kg, while 0% survival
was obtained with the 6.25 mg/kg dose (A-np) (Table 2).
To investigate the possibility of enhanced survival by the
antibiotic treatment in the presence of specific antibodies, group of
animals previously immunized with the Hs-np dilution and
challenged 1 h later with the lethal dose of the corresponding
bacteria were treated at 8 h intervals with the A-np for each strain.
Survival rates in mice infected with Strain 1 increased from 0% in
animals receiving either the HS-np or the A-np alone to 90% in
animals receiving the combination. In mice infected with Strain 2,
survival rates raised from 0% (A-np alone) or 10% (HS-np alone)
to 60% (HS-np+A-np), whereas in those infected with Strain 3,
survivals changed from 10% (A-np alone or HS-np alone) to 60%
(HS-np+A-np) (Tables 1 and 2). In the case of ceftriaxone and
Strain 2, survival rates increased from 0% to 20% (Table 2).
Significant differences were found between Kaplan-Meier survival
rates obtained with the combined strategy vs. HS-np alone or A-
np alone for cefditoren and Strain 1 (p,0.0001), Strain 2 (p#0.01)
and Strain 3 (p#0.05), but not for ceftriaxone and Strain
2 (p=0.1) (Figure 3). These results confirm that the efficacy
of cefditoren treatment against the non-susceptible strains
was markedly higher in the presence of specific antibodies to
S. pneumoniae.
Figure 2. In vitro opsonophagocytosis using fresh mice neutrophils. Flow cytometry histograms and the corresponding fluorescence indices
showing opsonophagocytosis for Strain 1 (A), Strain 3 (B), and Strain 2 with cefditoren (C) and ceftriaxone (D).
doi:10.1371/journal.pone.0012041.g002
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Strain 1 (serotype 6B; MICCDN=1mg/ml) Strain 3 (serotype 23F; MICCDN=4mg/ml)
Experimental group t.MIC ft/MIC % Survival at day 7 t.MIC ft/MIC % Survival at day 7
CDN (mg/kg)
Control - - 0 - - 0
6.25 21.6 13.1 0 15.8 4.9 ND
12.5 22.8 14.3 0 17.2 8.1 20
25 31.7 17.4 60 20.8 10.5 20
50 34.6 19.3 100 22.4 12.7 20
100 45.0 22.7 ND 27.3 15.8 60
HS
Control - - 0 - - 0
HS 1/4 - - 0 - - 0
HS 1/2 - - 40 - - 20
HS + CDN (mg/kg)
Control - - 0 - - 0
CDN
a 22.8 14.3 0 22.4 12.7 10
HS
b -- 0 - - 1 0
HS
b + CDN
a 22.8 14.3 90 22.4 12.7 60
a12.5 mg/kg for strain 1 and 50 mg/kg for strain 3
b1/4 dilution for strain 1 and 1/2 for strain 3
t.MIC, ft.MIC and survival at day 7 in animals infected with strains 1 and 3 obtained in experiments with dose-ranging cefditoren (CDN), dose-ranging hyperimmune
serum, and in experiments administering CDN in pre-immunized animals
doi:10.1371/journal.pone.0012041.t001
Table 2. Pharmacodymanics and efficacy against Strain 2.
Cefditoren (MIC=2 mg/ml) Ceftriaxone (MIC=4 mg/ml)
Experimental group t.MIC ft/MIC % Survival at day 7 t.MIC ft/MIC % Survival at day 7
Antibiotic (mg/kg)
Control - - 0 - - 0
6.25 18.7 9.6 0 20.6 0.0 0
12.5 19.9 11.3 20 26.9 5.4 80
25 24.5 13.7 0 41.1 8.7 100
50 26.8 16.0 0 45.6 11.9 100
100 36.1 19.2 100 ND
HS
Control - - 0 - - 0
HS 1/4 - - 20 - - 20
HS 1/2 - - 40 - - 40
HS + Antibiotic (mg/kg)
Control - - 0 - - 0
Antibiotic
a 26.8 16.0 0 20.6 0.0 0
HS
b - - 10 - - 0
HS
b + Antibiotic
a 26.8 16.0 60 20.6 0.0 20
a50 mg/kg for cefditoren and 6.25 mg/kg for ceftriaxone
b1/4 dilution
t.MIC, ft.MIC and survival at day 7 in animals infected with strain 2 (serotype 19F) obtained in experiments with dose-ranging cefditoren and ceftriaxone, dose-
ranging hyperimmune serum, and in experiments administering antibiotics in pre-immunized animals
doi:10.1371/journal.pone.0012041.t002
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pharmacodynamic parameters predicting efficacy
Pharmacokinetic and pharmacodynamic parameters for cefdi-
toren and ceftriaxone were calculated with concentrations
experimentally measured in mice sera (Table 3). Rates of protein
binding in mice sera were 86.9% for cefditoren and 91.9% for
ceftriaxone. In addition, t.MIC (total) and ft.MIC (free) were
calculated and related with percentages of survival at day 7 in mice
receiving the antibiotic (alone) or hyperimmune serum+antibiotic
(Tables 1 and 2). In non-pre-immunized animals, t.MIC values
for cefditoren of <35% for total drug (corresponding to <19% for
free drug) were associated with 100% survival (occurring with
50 mg/kg cefditoren for Strain 1, MIC=1 mg/ml, and with
100 mg/kg for Strain 2, MIC=2 mg/ml). Lower t.MIC values
(of 27.3% and 31.7% for total drug corresponding to 15.8% and
17.4% for free drug, respectively) were associated with 60%
survival, occurring with 25 mg/kg cefditoren for Strain 1
(MIC=1 mg/ml) and 100 mg/kg for Strain 3 (MIC=4 mg/ml),
respectively. When t.MIC values for cefditoren were lower than
26.8% for total drug (16.0% for free drug) survivals were ,20%
(12.5 mg/kg for Strain 1 or 50 mg/kg for Strains 2 and 3)
(Tables 1 and 2).
In the case of ceftriaxone and Strain 2 (MIC=4 mg/ml), 100%
survival was obtained with t.MIC of 41.1% for total drug (8.7%
for free drug) corresponding to a ceftriaxone 25 mg/kg adminis-
tration, while 0% survival was obtained with t.MIC of 20.6% for
total drug (0% free drug) corresponding to 6.25 mg/kg ceftriaxone
administration.
Figure 3. Therapeutic efficacy. Survival curves. Lines: continuous black (control), dotted black (antibiotic non-protective dose; A-np), dotted grey
(hyperimmune serum non-protective dilution; HS-np) and continuous grey (A-np treatment in animals pre-immunized with HS-np). (A) Strain 1 (A-np:
12.5 mg/kg; HS-np=1/4), (B) Strain 3 (A-np: 50 mg/kg; HS-np=1/2), (C) Strain 2 with cefditoren (A-np: 50 mg/kg; HS-np=1/4), and (D) Strain 2 with
ceftriaxone (A-np: 6.25 mg/kg; HS-np=1/4).
doi:10.1371/journal.pone.0012041.g003
Table 3. Pharmacokinetics.




6.25 53.0 0.9 30.4 6
12.5 168.4 1.1 64.1 8
25 232.5 0.9 101.3 8
50 290.6 1.1 124.4 8
Ceftriaxone (mg/kg)
6.25 28.6 0.9 24.0 2
12.5 101.2 0.9 54.8 4
25 483.7 0.9 158.8 6
Pharmacokinetic parameters of cefditoren and ceftriaxone from serum
concentrations experimentally determined in healthy animals
doi:10.1371/journal.pone.0012041.t003
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markedly decreased in pre-immunized animals and therefore with
specific antibodies in the systemic circulation: from <35% (<19%
free) to <25% (<15% free) for Strains 1 and 2, and from 27.3%
(15.8% free) to 22.4% (12.7% free) for Strain 3. Overall, cefditoren
t.MIC values linked to survival (90% for Strain 1 and 60% for
Strains 2 and 3) in pre-immunized animals with the HS-np
dilution were associated with ,10% survival rates in non-
immunized animals. This was not the case of ceftriaxone where
t.MIC values with the A-np dose were linked to survivals #20%,
regardless the pre-immunization or not of animals with the HS-np
dilution.
Early bacterial clearance of S. pneumoniae from the
bloodstream is associated with survival
To study the relationship between survival/mortality with rapid
bacterial clearance from blood, animals were grouped by outcome
at day 7 (one group for surviving animals and one for those dead at
day 7), regardless the study arm (control, HS-np, A-np or HS-
np+A-np). Median blood colony counts (cfu) per ml (cfu/ml) at
time 8 h (when all animals were still alive and prior to the
administration of second antibiotic dose) for the three strains were
significantly lower in animals surviving at day 7 than in those
dying from 8 h on: 8.25610
4 vs. 1.20610
6 for Strain 1 (serotype
6B), 1.14610
5 vs. 5.59610
8 for Strain 2 (serotype 19F) and
1.25610
4 vs. 3.55610
6 for Strain 3 (serotype 23F). These results
confirm that rapid reduction in bacterial load conditions
therapeutic outcomes, and that strategies associated with lower
mortality had a translation in rapid bacterial clearance.
Discussion
Preventive and therapeutic measures against S. pneumoniae as
vaccination and antibiotic therapy have modified not only the
disease burden but also resistances in this bacterial species. It is well
known that in invasive isolates penicillin/erythromycin non-
susceptibility is clustered in certain serotypes. The 7-valent
conjugate pneumococcal vaccine (PCV7), including serotypes most
associated to penicillin/erythromycin non-susceptibility, was intro-
duced for children immunization in 2000 s, impacting in the
current decade the prevalence of the different serotypes and
reversingthe increasing prevalenceof penicillinnon-susceptibilityin
S. pneumoniae in previous decades, with a herd effect in adults [9,10].
The strains used in the present study were selected, among
strains belonging to serotypes included in currently available
pneumococcal vaccines, based on their high penicillin MIC (the
lower the in vitro activity of the antibiotic, the greater the chance
to evidence the potential in vivo synergism between antibiotic
serum concentrations and immunoglobulins present by passive
immunization). For this reason, MICs of penicillin, cefditoren and
ceftriaxone for the three study strains are higher than MIC90
values of the three compounds in published surveillance studies
[11,12]. The strains of this study belonged to serotypes 6B, 19F
and 23F, thus synergism was explored against serotypes included
in immunization campaigns. In a recent in vitro study analyzing
clinical isolates that exhibited very high penicillin, cefotaxime and
amoxicillin resistance (MIC$16 mg/ml) associated with resistance
to all oral b-lactams and macrolides, all isolates belonged to
serotypes 19F and 23F [13,14]. In addition, isolation of serotypes
6B, 19F and 23F (among PCV7 serotypes) has been identified as
an independent risk factor for 30-day mortality in bacteremic
disease in a recently published study [15]. It is in this context, with
troublesome strains, where therapeutic strategies present added
value since these strains are a challenge for antibiotic treatment.
In vivo, antibiotics interact with bacteria in a more complex way
than in vitro due to the presence of serum proteins acting as an
interface. While specific immunoglobulins and complement may
enhance antibacterial activity of b-lactams, albumin may limitate
its activity in highly bound agents. Apart from exploring combined
effects of antibiotics and the immune system, the study arms
consisting in antibiotic administration alone (in non-immunized
animals) provided interesting pharmacodynamic information on
cefditoren and ceftriaxone, considering their similar protein
binding rates in mice and humans. An in vitro approach to the
influence of protein binding on the cefditoren activity was
performed in a previous in vitro pharmacodynamic simulation
over 24 h of serum concentrations (achieved after 400 mg
cefditoren bid administration) using broth containing physiological
concentrations of human albumin (4 g/dl) against four S.
pneumoniae isolates exhibiting MICs of 0.25 and 0.5 mg/ml [16].
In that study, reductions in the initial inocula were .99.9% for the
strain with MIC=0.25 mg/ml and from 52.9% to 96.8% for the
strain with MIC=0.5 mg/ml, with free t.MIC values #24%
(experimental protein binding of 87.1%) [16]. In the present
animal model, total t.MIC of <35% (ft.MIC values of 20%)
were associated with therapeutic efficacy of cefditoren (with an
experimentally measured binding rate of 86.9% in mice serum),
using as infecting strains isolates with cefditoren MICs of 1, 2 or
4 mg/ml. Monte Carlo simulations have estimated that serum
concentrations of cefditoren after 400 mg bid administration in
humans exceed MICs of 1 mg/ml for 44.1% of the dosing interval
[17]; the results of the present model suggesting the appropriate-
ness of this t.MIC value for pharmacodynamic efficacy of
cefditoren.
Animal models, as pragmatic studies, have been critical to our
understanding of PK/PD relationships to estimate which phar-
macodynamic parameter is the best predictor (neutropenic animal
models) and the magnitude of this parameter (immunocompetent
animal models) [18]. However explicative animal models are
needed in the case of S. pneumoniae since, as previously commented,
antibodies to capsular polysaccharides are likely to be present
before infection because colonization is an immunizing event and
preventive measures as vaccination are increasingly being used.
Previous animal models using a serotype 6B isolate as infecting
strain showed the lower t.MIC value (total drug) associated with
100% survival in immunized vs. non-immunized animals [5] for
amoxicillin and cefotaxime. If synergism could be expected for
other b-lactams or other serotypes remained to be explored. The
benefit of the synergism would be not the antibiotic dose decrease
but the coverage of strains with high MIC. In the current model
previous passive immunization of animals resulted in a decrease in
t.MIC values for cefditoren associated with efficacy against the
three study strains belonging to serotypes 6B, 19F and 23F. While
in immunized animals t.MIC values of 22.8% (total) and 14%
(free) for cefditoren were associated with 90% survival for Strain 1
and 60% survival (with similar t.MIC values) for Strains 2 and 3,
these t.MIC values were associated with survivals ,10% in non-
immunized animals (absence of specific antibodies). However this
was not observed for ceftriaxone where no synergism (or even
more collaboration) of ceftriaxone and specific antibiotics was
demonstrated (total t.MIC values of 20.6% were not efficacious
regardless the presence or not of specific antibodies). A possible
explanation for this could be that all ceftriaxone binds serum
proteins under the combined treatment conditions implying that
no free ceftriaxone was available (negligible free t.MIC for total
t.MIC values of 20.6%) for the potential enhanced phagocytosis
and protection. In addition in vitro opsonophagocytosis experi-
ments showed that the collaboration of specific antibodies and
Drugs & Immunity & Pneumococci
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ceftriaxone against Strain 2 when using mice neutrophils, with a
lack of collaboration (for ceftriaxone) when using HL-60 cells.
Subinhibitory concentrations of cefditoren significantly enhanced
the phagocytosis produced by the hyperimmune serum (1/10
dilution) against the three serotypes tested regardless the source of
neutrophils used. For extracellular capsulated pathogens such as S.
pneumoniae, phagocytosis is thought to be an important immune
mechanism for controlling infection [19,20]. Although there has
been considerable emphasis on the role of anticapsular antibodies
for immunity to S. pneumoniae in vaccinated individuals, comple-
ment and antibodies to non-capsular antigens are likely to be
important [21]. The present study was performed with hyperim-
mune serum obtained by mice immunisation with heat-inactivated
whole cell S. pneumoniae. Our results confirmed that phagocytosis
mediated by professional phagocytes was increased in the presence
of subinhibitory concentrations of cefditoren and specific antibod-
ies to S. pneumoniae (in a higher extend in experiments with fresh
mice neutrophils).
The objective of antibiotic treatment is the rapid decrease of
bacterial load. Recently, bacterial load in patients with pneumo-
coccal pneumonia has been associated with failure (likelihood of
death) [22]. Previous animal models showed the effect of specific
antibodies or b-lactams (amoxicillin and cefotaxime) on the
bacteremic profile over 7 days and its relation with mortality
[3,4]. In the present study the bacteremic profile was also related
with mortality (data not shown), but we further investigated
mortality prediction by means of relating bacterial counts in blood
in the 8 h-period after the first dose administration with mortality
from 8 h on, as a marker of the importance of rapid clearance of
bacteria (in vivo bactericidal activity) on the therapeutic outcome.
At 8 h (prior to the second dose administration), when all animals
were still alive (including controls), the group of animals dead at
day 7 (regardless the day of death) showed high median bacterial
counts ($1.20610
6 cfu/ml) whereas in the group of surviving
animals at day 7, median bacterial counts were lower
(#1.14610
5 cfu/ml). This stresses the importance of rapid
antibacterial activity producing early reduction of the bacterial
load for therapeutic efficacy.
The results of this study show that in mice, where the protein
binding rate is similar to the one in humans, cefditoren total
t.MIC values of <35% were linked to therapeutic efficacy, and
the required values decreased when animals were pre-immunized.
Early clearance of microorganisms from blood (rapid antibacterial
activity) was associated with survival. The combined effects of
cefditoren and hyperimmune serum against the three strains from
serotypes 6B, 19F and 23F reinforce the idea that the development
of immunoprotection to overcome resistance may potentially
provide new lifesaving strategies [23].
Materials and Methods
Strains
Three S. pneumoniae strains were used throughout the study:
Strain 1 (serotype 6B; penicillin MIC=2 mg/ml, cefditoren
MIC=1 mg/ml), Strain 2 (serotype 19F; penicillin MIC=1 mg/
ml, cefditoren MIC=2 mg/ml, ceftriaxone MIC=4 mg/ml), and
Strain 3 (serotype 23F; penicillin MIC=16 mg/ml, cefditoren
MIC=4 mg/ml). Microorganisms were grown in Todd-Hewitt
broth supplemented with 0.5% yeast extract (Difco, Detroit,
Mich.), aliquoted, and stored at 280uC in Todd-Hewitt broth
with 10% glycerol. These bacterial aliquots were used in all the
following experiments.
Antibiotics
Powers of known potency of cefditoren (Tedec-Meiji Farma
S.A, Madrid, Spain) and ceftriaxone (Sigma-Aldrich Chemical
Co., St Louis, MO) were used in experiments carried out with the
three strains in the case of cefditoren and Strain 2 in the case of
ceftriaxone.
Animals
BALB/c female mice aged from 8 to 12 weeks weighing 19 to
22 g were purchased from Harlan Laboratories Models (Barce-
lona, Spain).
Ethics Statement
Prevailing regulations regarding the care and use of laboratory
animals in Spain and the European Community were followed
throughout the study. The protocol of the study was approved by
the Ethical Committee for Animal Experimentation of Universi-
dad Complutense, Madrid (Spain) (Approval certificate issued on
February 20th, 2009).
Hyperimmune serum
Hyperimmune serum from the different strains was obtained as
previously described [6]. Briefly, bacteria in the logarithmic phase
of growth were inactivated by heat treatment at 60uC for 1 h,
confirming the absence of live bacteria in the immunogenic
suspension by plating a small volume onto blood agar plates. The
antigenic suspension was kept at 270uC as small aliquots for
further inoculations. Groups of 20 mice were inoculated weekly
(up to five weeks) by the intraperitoneal route, with 200 ml of the
inactivated bacterial suspension containing 10
7 cfu/ml of the
corresponding strain. The animals were exsanguinated by cardiac
puncture to obtain the serum. Levels of specific IgG antibodies to
capsular serotypes 6B, 19F and 23F were determined for both the
pre-immune and immune sera by using the Nab IgG Plus Spin
Column (PierceH, Rockford, USA) and a Bradford dye protein
assay [24]. Hyperimmune sera were aliquoted and stored at -70uC
for further use both in the in vitro and in vivo studies (see below).
Opsonophagocytosis
To explore the effect of combining sub-inhibitory antibiotic
concentrations and specific antibodies on the interaction of S.
pneumoniae with phagocytes, the level of phagocytosis was measured
by using a previously described flow cytometry opsonophagocytic
assay including fluorescent bacteria and a neutrophil cell line
[25,26]. In addition the assay was performed using fresh
neutrophils isolated from mice peripheral blood following
previously described methods [27]. S. pneumoniae strains were
fluorescently labelled by incubation with 5,6-carboxyfluorescein-
succinimidyl ester (FAM-SE; Molecular Probes, Eugene, OR)
solution (10 mg/ml in dimethyl sulfoxide; Sigma) in 0.1 M sodium
bicarbonate buffer for 1 h at 37uC, washed five times with Hanks
balanced salt solution (HBSS) and stored in aliquots at 270uCi n
10% glycerol (approximately 10
9 cfu/ml) for further use. The cell
line HL-60 (CCL240; American Type Culture Collection, Rock-
ville, Maryland) was used to provide the effector cells after
differentiation into granulocytes by using previously described
protocols [25,26,28]. Differentiation was confirmed before the
assays using a monoclonal antibody to CD11b (kindly supplied by
Dr. C. Bernabeu, CIB-CSIC) which is a useful marker of
granulocytic differentiation [29]. HL-60 cells were harvested by
centrifugation and washed twice with HBSS and once with HBSS
in the presence of calcium and magnesium ions. FAM-SE labeled
bacteria (10
6 cfu) were opsonized with hyperimmune serum
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concentrations (0.256or 0.56MIC) of cefditoren (Strains 1, 2
and 3) or ceftriaxone (Strain 2) for 1 h at 37uC with 150 rpm
shaking. Negative controls, using the same volume of HBSS, were
also included [25,26]. HL-60 cells (10
5 cfu/well) were added to
opsonized bacteria in a microtiter plate and incubated for 30
minutes at 37uC with shaking, after which the bacteria and cells
were fixed using 3% paraformaldehyde and analyzed using a
Cytomics FC500 Beckman Coulter flow cytometer (Beckman
Coulter, Miami, USA). A minimum of 6000 cells per sample were
analyzed. Results were expressed as fluorescence index defined as
the proportion of positive neutrophils for fluorescent bacteria
multiplied by the geometric mean fluorescence intensity (MFI)
which correlates with the amount of bacteria phagocytosed per cell
[26,30]. Control experiments with strain no. 2, pre- and post-
opsonization confirmed that bacterial fluorescence was not
affected by opsonization with serum or by the presence of
antibiotics (data not shown).
The two-tailed Student’s t-test was used to compare fluores-
cence indices obtained with the different experimental groups.
Animal model
Determination of the minimal lethal dose. Groups of 5
mice per dilution were inoculated intraperitoneally (i.p.) with






8 cfu/ml (spectrophotometrically measured) to
determine the minimal dose that produced a 100% mortality
rate over a 7-day follow-up period (i.e., the minimal lethal dose).
Determination of protection by hyperimmune serum.
Groups of five mice per dilution were inoculated i.p. with 200 mlo f
serial doubling dilutions of hyperimmune serum ranging from one-
half to one-eighth. The animals included in the control group were
injected with a placebo (phosphate buffer saline, PBS). After 1 h,
the mice received one lethal dose of bacteria by the i.p. route. The
animals were observed for 7 days. The first dilution showing 100%
(or the highest) mortality was considered the non-protecting
dilution of hyperimmune serum (HS-np).
Determination of protection by antibiotics. Groups of
five mice per antibiotic dose were infected i.p. with one lethal dose
of bacteria. After 1 h, animals were treated three times a day for
48 h by administering 100 ml by the subcutaneous route in a dose-
ranging study, with the doses ranging from 6.25 to 100 mg/kg of
body weight. The animals included in the control group received
PBS. The animals were observed, and the numbers of deaths were
recorded for 7 days.
The highest dose that produced 0% (or the lowest) survival rate
was considered the non-protective dose (A-np).
Determination of antibiotic protection in the presence of
antibodies. Groups of 10 animals received a single i.p. dose of
hyperimmune serum (using the HS-np dilution) administered 1 h
prior to i.p. inoculation of the bacterial minimal lethal dose.
Antibiotic treatment with the A-np dose was initiated 1 h after the
pneumococal challenge and was continued every 8 h, with a total
of six subcutaneous doses being administered. The animals were
observed, and the numbers of deaths were recorded for 7 days. On
each day of inoculation, three control groups were used: one
received placebo, one received the HS-np alone and one received
the A-np regimen alone.
An ordinal log-rank (Mantel-Cox) test was used to compare
survivals in experimental groups.
Determination of bacterial counts in serum. Bacteremic
profiles (colony counts in blood) were determined in the groups of
10 animals receiving the combined HS-np+A-np treatment as well
as in the three control groups mentioned above. To this end, five
animals per group were randomly chosen and blood samples were
collected at 2, 4, 6, 8, 24, 48, 72, 96, 120, 144 and 168 h post-
infection (only from live animals). To collect blood samples, tails
were disinfected and anaesthetized (local anaesthesia; ethyl
chloride, Cloretilo Cheminosa, Ern, Barcelona, Spain), and the
terminal portion of the tail was eliminated with scissors. An 8-ml
blood sample was collected by pressing the tail, resuspended in
Todd-Hewitt broth containing 50 units of heparin (Calbiochem,
Darmstadt, Germany), and plated onto blood agar for colony
counting. To obtain the subsequent blood samples, the crust was
removed and again, by pressing the anaesthetized tail, an 8-ml
blood sample was collected and processed. This procedure ensured
that blood collection did not compromise mouse survivability as
previously demonstrated [3,4]. The lower limit of detection was
10
2 cfu/ml.
Determination of antibiotic concentrations in serum.
Concentrations in serum were determined in healthy animals after
administration of a single subcutaneous dose of all antibiotic doses
tested in the antibiotic dose-ranging studies. Blood samples were
collected at 0.25, 0.5 1, 2, 4, 6, and 8 h after dosing from groups of
two animals per dose, timepoint and antibiotic. Concentrations
were measured by bioassay with Morganella morganii ATCC 8076H
for cefditoren and Escherichia coli NCTC 10418 for ceftriaxone as
reference organisms.
Pharmacokinetic analysis. Protein binding in mice serum
was measured by an ultrafiltration method described by Craig and
Suh [31] for cefditoren and ceftriaxone concentrations of 4 mg/ml
and 64 mg/ml, respectively, by using a centrifugal system device
(CentrifreeH, Amicon Bioseparations, Millipore, Tullagreen,
Ireland). Antibiotic concentrations in mice serum (pre-filtered
samples) and in ultrafiltrates recovered in the polyethylene filtrate
cups were measured by bioassay (see above). Percentages of
antibiotics bound to mice serum proteins were calculated using the
expression:
[antibiotic in serum]-[antibiotic in ultrafiltrates]/[antibiotic in
serum]6100.
Experimentally determined values of protein binding in mice
serum was used for calculating free concentrations of each
antibiotic.
Total and free concentrations for each antibiotic were analyzed
by a noncompartmental approach with the 5.2 Win-Nonlin
program (Pharsight, Mountain View, CA.). The theoretical
concentration at time zero (obtained by back extrapolation to
the origin of the elimination regression line) and t1/2 was
calculated by least-squares non-lineal regression analysis. The area
under the serum concentration-time curves (AUCs) from time zero
to infinity was calculated by the trapezoidal rule. t.MIC and free
t.MIC (ft.MIC) were calculated graphically from the semilog-
arithmic plot of the concentration (total or free)-time data.
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